Vir Biotechnology, Inc. VIR Financial Assets Amortized Cost Basis
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:FinancialAssetsAmortizedCostBasis.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s financial assets amortized cost basis.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s financial assets amortized cost basis?
- Vir Biotechnology, Inc. (VIR) reported financial assets amortized cost basis of $776.58M in Q1 2026.
- How has Vir Biotechnology, Inc.'s financial assets amortized cost basis changed year-over-year?
- Vir Biotechnology, Inc.'s financial assets amortized cost basis decreased by 21.5% year-over-year, from $989.09M to $776.58M.
- What is the long-term trend for Vir Biotechnology, Inc.'s financial assets amortized cost basis?
- Over 3 years (2022 to 2025), Vir Biotechnology, Inc.'s financial assets amortized cost basis has grown at a -34.2% compound annual growth rate (CAGR), from $2.4B to $683.36M.